BACKGROUND: Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia in children. The COVID-19 pandemic and associated public health interventions have significantly influenced the epidemiology of respiratory infections. This single-center retrospective cohort study aimed to evaluate changes in MP infection patterns among children before, during, and after the COVID-19 pandemic. METHODS: We analyzed data from 15,718 pediatric patients (aged 1–18 years) with CAP admitted to Shaanxi Provincial People’s Hospital between January 2017 and December 2023. The study periods were defined as pre-pandemic (January 1, 2017, to January 22, 2020), pandemic (January 23, 2020, to December 11, 2022), and post-pandemic (December 12, 2022, to December 31, 2023). Epidemiological characteristics of MP infections were assessed using descriptive statistics and regression analysis. RESULTS: Among the 15,718 patients, 5,454 (34.7%) tested positive for MP. The highest positivity rate was observed in children aged > 6 years (52.4%), with a male predominance across all age groups. Most infections occurred in autumn (41.5%). The MP positivity rate was lowest during the pandemic period and highest in the post-pandemic period (P < 0.001). Regression analysis indicated a broadening of the susceptible age range following the pandemic onset. CONCLUSION: COVID-19 containment measures altered the transmission dynamics of MP, affecting demographic characteristics such as age distribution and seasonal trends. Continuous surveillance of MP epidemiology in the post-pandemic era is recommended to inform clinical management and public health strategies.

Objective: To investigate the distribution characteristics of pegaspargase blood concentration at 7 days after administration in children with acute lymphoblastic leukemia (ALL) treated with pegaspargase, its correlation with common adverse reactions, screen the early warning thresholds for adverse reactions, and evaluate the clinical feasibility of single-time-point therapeutic drug monitoring (TDM). Methods: A single-center, prospective observational design was adopted, enrolling 65 children with ALL aged 1-18 years who all received a standardized chemotherapy regimen containing pegaspargase (dose: 2500 IU/m², intramuscular injection every 14 days). Peripheral blood was collected on the 7th day after the first administration, and pegaspargase blood concentration was detected by enzyme-linked immunosorbent assay (ELISA). Patients were divided into low, medium, and high concentration groups according to quartiles. Adverse reactions such as liver injury and coagulation abnormalities were evaluated with reference to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTC) Version 5.0. Early warning thresholds were screened by Spearman correlation analysis and receiver operating characteristic (ROC) curve. Results: A total of 60 valid samples were finally obtained. The blood concentration of pegaspargase at 7 days after administration showed a normal distribution, with a mean of (16.8±7.5) IU/L, a median of 15.9 IU/L, and an interquartile range of [10.3, 22.5] IU/L. Eighty percent of the children had a concentration ≥10 IU/L (the sufficient activity threshold recommended by the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)). The incidence rates of liver injury (60.0%) and coagulation abnormalities (46.7%) in the high concentration group (>22.5 IU/L) were significantly higher than those in the low concentration group (13.3% and 6.7%) (P<0.05). The blood concentration was moderately positively correlated with ALT (r_s=0.426), AST (r_s=0.389), PT (r_s=0.365), and APTT (r_s=0.328) (P<0.01). The optimal early warning thresholds for grade ≥2 liver injury and coagulation abnormalities were 18.7 IU/L (AUC=0.836) and 20.3 IU/L (AUC=0.792), respectively. There was no significant correlation between blood concentration and hyperglycemia or allergic reactions (P>0.05). Conclusion: The ideal reference interval of pegaspargase blood concentration at 7 days after administration in Chinese children and adolescents with ALL is 10.3-22.5 IU/L, and 18.7 IU/L and 20.3 IU/L can be used as the early warning thresholds for liver injury and coagulation abnormalities, respectively. The single-time-point TDM scheme at 7 days after administration is convenient to operate and reliable in results, which can be used for clinical individualized medication guidance and reduce the risk of adverse reactions. These findings provide a localized basis for individualized medication and toxicity early warning of pegaspargase in Chinese pediatric ALL, and promote the clinical application of single-time-point TDM.

Introduction: To analyze the clinical characteristics and influencing factors of drug-induced liver injury (DILI) in pediatric patients with newly diagnosed Acute Lymphoblastic Leukemia (ALL) during chemotherapy, using a retrospective analysis. Methods: A retrospective analysis was conducted on 189 pediatric ALL patients treated at our institution from January 2019 to March 2024. The incidence and related factors of DILI were assessed, including body mass index (BMI), vitamin D levels, absolute neutrophil counts, and the number of blood transfusions. Results: The study found that the incidence of DILI was 21.34%. Statistical analysis indicated that BMI, vitamin D levels, absolute neutrophil counts, and the number of transfusions were independent factors influencing the occurrence of DILI during chemotherapy in children with ALL (P<0.05). Moreover, DILI presented in various forms, predominantly as hepatocellular injury, mixed type, and cholestatic type, with hepatocellular injury being the most common. Conclusion: Body mass index, vitamin D levels, absolute neutrophil counts, and the number of transfusions are critical independent factors affecting the development of drug-induced liver injury in pediatric patients with acute leukemia during chemotherapy. In clinical practice, proactive intervention on these factors is essential. Prompt actions such as discontinuing or adjusting medication dosages, hepatic protection, enzyme reduction, and jaundice management are vital to ensure the recovery of all patients.

Background : Epilepsy is a prevalent neurobehavioral disorder, which affects more the 50 million individuals worldwide. It is characterized by neuron hyperexcitability mediated by repetitive convulsions. The current investigation was planned to study the therapeutic properties of the xanthohumol against pentylenetetrazol (PTZ)-induced convulsions in mice by regulating inflammation and oxidative stress. Methods : The 70 mg/kg of PTZ was administered (i.p.) to the mice for stimulating the epileptic seizures and 20 mg/kg of xanthohumol was pre-treated by oral route before the 30 min of PTZ administration. The mice were observed closely for 30 min after the PTZ treatment to detect the onset and duration of clonic/tonic convulsions and mortality. The status of glutamate, GABA, dopamine, Na + K + ATPase, and Ca + ATPase were quantified using respective kits. The level of MDA, NO, GSH, and SOD were detected using standard methods. The levels of inflammatory biomarkers such as COX-2, TNF- α , NF- κ B, TLR-4, and IL-1 β in the brain tissues were inspected using kits. The histopathological analysis was done on the brain tissues. Results : The xanthohumol significantly ( p < 0.05) reduced the onset and duration of convulsions, mortality, and behavioral changes in the epileptic mice. The levels of COX-2, TNF- α , NF- κ B, TLR-4, and IL-1 β were significantly ( p < 0.05) decreased in the epileptic mice by 20 mg/kg xanthohumol treatment. The levels of MDA and NO was reduced and GSH and SOD were increased by the 20 mg/kg xanthohumol treatment. The 20 mg/kg xanthohumol significantly ( p < 0.05) decreased the glutamate and improved the dopamine, GABA, Na + K + ATPase, and Ca + ATPase in the epileptic mice. The findings of histopathological studies revealed that 20 mg/kg xanthohumol decreased the inflammatory signs and pyknosis in the brain tissues. Conclusion : Pre-treatment with the 20 mg/kg xanthohumol ameliorates the PTZ-triggered seizures in a mice model through its antioxidant and anti-inflammatory potentials. Hence, xanthohumol can be a promising antiepileptic candidate in the future to treat epilepsy.

OBJECTIVE:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy, and T-ALL patients are prone to early disease relapse and suffer from poor outcomes. The crucial function of RNA-binding proteins (RBPs) has been reported in the progression of cancers by regulating the expression of transcripts. This study aimed to reveal the role and molecular regulatory mechanism of RBP Pumilio2 (PUM2) in T-ALL.METHODS:The expression of genes was detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. The viability, proliferation, and apoptosis of T-ALL cells were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5-ethynyl-2'-deoxyuridine, and flow cytometry analysis. Luciferase reporter, RNA pulldown, and RNA immunoprecipitation assays were performed to confirm the binding of PUM2 to RBM5. The combination between RNA-binding motif protein 5 (RBM5) and microRNA (miR)-28-5p was validated using luciferase reporter assay.RESULTS:Our data revealed that PUM2 was highly expressed in T-ALL blood samples and cell lines. PUM2 knockdown suppressed the proliferation but accelerated the apoptosis of T-ALL cells in vitro. Additionally, RBM5 exhibited a low expression level in T-ALL samples and cells. PUM2 negatively regulated RBM5 via targeting its 3'untranslated region (3'UTR). Moreover, PUM2 competitively bound to RBM5 3'UTR with miR-28-5p. Rescue experiments showed that RBM5 knockdown reversed the anti-tumor effects mediated by PUM2 knockdown in T-ALL cells.CONCLUSION:PUM2 plays as a novel oncogenic RBP in T-ALL by competitively binding to RBM5 mRNA with miR-28-5p.

目的:探究布地奈德混悬液对哮喘模型小鼠肺组织TOLL样受体4(toll-like receptor4,TLR4)/髓样分化因子88 (myeloid differentiation factor 88,MyD88)/核因子κB (nuclear factor-κB,NF-κB)通路的影响.方法:使用4％鸡蛋清白蛋白与2％的Al(OH3)共同致敏小鼠,建立咳嗽变异性哮喘小鼠模型40只,将模型大鼠分另别使用低、中、高剂量(0.2、1.0、2.0 g/kg)布地奈德混悬液和孟鲁司特钠进行干预,1次/日连续干预14 d,于干预14d时采集小鼠的支气管肺泡灌注液(bronchoalveolar lavage fluid,BALF)、气管及肺组织,对各组BALF中的白细胞(white blood cell,WBC)、嗜酸性粒细胞、血清γ干扰素(interferon-γ,IFN-γ)、白细胞介素-1β (interleukin-1β,Il-1β)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)水平差异开展比较,对各组小鼠肺组织黏膜上皮增生程度评分、炎症细胞浸润程度评分、病变总评分差异,以及TLR4、MyD88、p65蛋白表达差异进行分析.结果:分析显示,布地奈德混悬液能够显著降低哮喘模型小鼠BALF中白细胞及嗜酸性粒细胞数量,同时还能够改善小鼠气管和支气管黏膜上皮增生与肺组织炎症细胞浸润状态,且干预后小鼠肺组织中的TLR4、MyD88、p65蛋白表达水平出现了明显的降低.结论:布地奈德混悬液对改善小鼠哮喘效果较好,其作用机制可能与该药能够调节TLR4、MyD88、p65蛋白表达,进而影响炎症和免疫反应进程有关.

目的 探讨甲泼尼龙冲击疗法治疗小儿过敏性紫癜的临床效果及其对炎性因子的影响.方法 选取2018年1月至2019年4月榆林市第一医院收治的小儿过敏性紫癜病人100例,按随机数字表法分为对照组和观察组,每组50例.对照组给予孟鲁司特钠治疗,观察组病人在对照组基础上给予甲泼尼龙.观察两组病人治疗后临床效果和不良反应,临床症状缓解时间,以及治疗前后血清白细胞介素-6(IL-6),白细胞介素-10(IL-10),肿瘤坏死因子-α(TNF-α),免疫球蛋白A(IgA),免疫球蛋白M(IgM),免疫球蛋白E(IgE)含量变化.结果 观察组临床总有效率(96％)高于对照组(82％),不良反应发生率(4％)低于对照组(22％),差异有统计学意义(P<0.05).观察组病人紫癜消退时间、关节疼痛改善时间、消化道症状改善时间分别为(7.74±1.26)、(3.24±1.13)、(3.72±1.12)d,对照组分别为(8.56±1.32)、(5.42±1.27)、(5.48±1.13)d,观察组均短于对照组,差异有统计学意义(P<0.05).观察组治疗后IL-6、IL-10、TNF-α、IgA、IgM及IgE水平分别为(23.71±7.14)、(40.73±9.91)、(47.72±7.14)、(2.55±0.45)、(1.11±0.34)、(108.32±17.17)g/L,对照组分别为(27.44±7.22)、(53.31±16.24)、(62.17±7.24)、(3.54±0.43)、(1.28±0.33)、(48.32±17.17)g/L,观察组均低于对照组,差异有统计学意义(P<0.05).结论 甲泼尼龙治疗小儿过敏性紫癜具有较好的临床治疗效果,可有效改善病人的临床症状,降低炎性因子水平,且不良反应率较低,值得临床应用.

目的:探讨曲普瑞林联合小剂量生长激素物治疗女童CPP疗效及对骨龄影响.方法:选取2017年1月至2020年1月我院收治的200例CPP女童,随机将其分为两组,对照组100例,给予常规治疗,研究组100例,给予曲普瑞林联合小剂量生长激素治疗.观察两组患者的临床疗效、治疗前后血清性激素水平、子宫容积、卵巢容积变化情况以及生长发育指标变化.结果:治疗后,研究组总有效率为98％;显著高于对照组总有效率(80％,P＜0.05).两组FSH、LH、E2水平、子宫容积、卵巢容积均降低,骨龄、身高、PAH均显著升高,且研究组上述指标明显优于对照组(P＜0.05).结论:曲普瑞林联合小剂量生长激素物治疗女童CPP疗效显著,能很好的改善患者血清性激素水平、子宫容积、卵巢容积,对生长发育指标具有积极的意义,值得临床推广和应用.

The present study was aimed to explore the neuroprotective role of imatinib in global ischemia-reperfusion-induced cerebral injury along with possible mechanisms. Global ischemia was induced in mice by bilateral carotid artery occlusion for 20 min, which was followed by reperfusion for 24 h by restoring the blood flow to the brain. The extent of cerebral injury was assessed after 24 h of global ischemia by measuring the locomotor activity (actophotometer test), motor coordination (inclined beam walking test), neurological severity score, learning and memory (object recognition test) and cerebral infarction (triphenyl tetrazolium chloride stain). ischemia-reperfusion injury produced significant cerebral infarction, impaired the behavioral parameters and decreased the expression of connexin 43 and phosphorylated signal transducer and activator of transcription 3 (p-STAT3) in the brain. A single dose administration of imatinib (20 and 40 mg/kg) attenuated ischemia-reperfusioninduced behavioral deficits and the extent of cerebral infarction along with the restoration of connexin 43 and p-STAT3 levels. However, administration of AG490, a selective Janus-activated kinase 2 (JAK2)/STAT3 inhibitor, abolished the neuroprotective actions of imatinib and decreased the expression of connexin 43 and p-STAT3. It is concluded that imatinib has the potential of attenuating global ischemia-reperfusion-induced cerebral injury, which may be possibly attributed to activation of JAK2/STAT3 signaling pathway along with the increase in the expression of connexin 43.

目的 探讨儿童过敏性紫癜(HSP)血浆干扰素-γ(IFN-γ)、白细胞介素-6(IL-6)、白细胞介素-17(IL-17)、转化生长因子-β1(TGF-β1)表达水平在评价紫癜性肾炎(HSPN)中的临床意义.方法 HSP急性期患儿138例为研究对象,依据是否合并HSPN分为HSP组(n=94例)和HSPN组(n=44例),同期选择健康体检的儿童50例为对照组.检测3组受试儿童血浆炎性细胞因子IFN-γ、IL-6、IL-17、TGF-β1水平,采用多元Logistic回归分析此类炎性细胞因子表达水平与HSPN发生的关系,并绘制利用受试者工作特征(ROC)曲线评价其与HSPN发生的临床价值.结果 HSPN组血浆IFN-γ、IL-6、IL-17、TGF-β1表达水平高于HSP组,HSP组高于对照组(P<0.05),3组比较差异有统计学意义(P<0.05).多元Logistic回归分析显示IFN-γ、IL-6、IL-17和TGF-β1与HSPN的发生呈独立正相关(OR分别为1.984,2.259,2.763和1.875,P<0.05).ROC曲线分析显示IFN-γ、IL-6、IL-17和TGF-β1预测HSPN的曲线下面积(AUC)分别为0.728、0.814、0.869和0.656.敏感性分别为81.12％、80.62％、87.42％和73.81％,特异性分别为70.40％、83.27％、84.56％和72.71％,最佳界限值分别为12.60、18.16、74.38、6.97 pg/ml.结论 IFN-γ、IL-6、IL-17、TGF-β1表达水平增高可能参与了HSP及其HSPN的发病,与HSPN的发生呈正相关,可作为早期诊断和预测HSPN发生的有效指标,临床应当密切关注此类炎性细胞因子的变化以指导临床预后评估.

目的 探讨过敏性紫癜患儿外周血miR-155表达及与Th17/Treg平衡的关系. 方法 选取79例过敏性紫癜患儿为研究对象,60例健康体检儿童作为对照,采用qRT-PCR技术检测外周血miR-155、RORγt和Foxp3 mRNA表达,流式细胞术检测Th17和Treg细胞比例,酶联免疫吸附法检测细胞因子IL-6、IL-17、IL-22、IL-23、IL-10和TGF-β1表达,Pearson相关性分析miR-155与Th17和Treg细胞,RORγt和Foxp3 mRNA,细胞因子IL-6、IL-17、IL-22、IL-23、IL-10和TGF-β1表达之间关系. 结果 与健康对照相比,过敏性紫癜患儿外周血miR-155、Th17细胞比例、转录因子RORγt、相关细胞因子IL-6、IL-17、IL-22和IL-23均显著升高(P＜0.05),Treg细胞比例、转录因子Foxp3、相关细胞因子IL-10和TGF-β1均显著降低(P＜0.05).miR-155与Th17细胞比例、RORγt、IL-6、IL-17、IL-22和IL-23均呈正相关(P＜0.05),与Treg细胞比例、Foxp3、IL-1O和TGF-β1均呈负相关(P＜0.05). 结论 过敏性紫癜患儿外周血miR-155高表达,Th17/Treg平衡失调,miR-155可能通过调节Th17/Treg平衡参与过敏性紫癜的疾病过程,是该疾病潜在的治疗靶点.

目的:探讨二维超声斑点追踪(2D-STI)及三维超声斑点追踪(3D-STI)技术评估川崎病患儿心肌功能的价值分析.方法:回顾性分析本院收治的92例川崎病患儿作为研究对象,将其中行3D-STI检查的50例患儿作为观察组,行2D-STI检查的42例患儿作为对照组,观察两组左室收缩功能指标、储存与分析图像时间、冠脉内径大小及左室基底段、中间段、心尖段、整段应变差异.结果:观察组左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)、左室心肌质量(LVMI)水平均高于对照组(P＜0.05),两组左室射血分数(LVEF)比较,差异无统计学意义(P＞0.05);观察组存储图像时间、分析图像时间均明显低于对照组(P＜0.05);观察组左冠状动脉(LCA)、右冠状动脉(RCA)均大于对照组(P＜0.05),两组左前降支(LAD)比较,差异无统计学意义(P＞0.05);观察组基底段、心尖段收缩期纵向峰值应变(LS)、收缩期圆周峰值应变(CS)、收缩期径向峰值应变(RS)均高于对照组(P＜0.05);观察组整体纵向峰值应变(GLS)、整体圆周峰值应变(GCS)、整体径向峰值应变(GRS)均高于对照组(P＜0.05);观察组中间段LS、CS高于对照组(P＜0.05).结论:3D-STI较2D-STI更能客观、准确的反应川崎病患儿心肌功能.

Objective: To explore the influencing factors of febrile convulsion. Methods: 110 cases of febrile convulsions whotreated from January 2016 to December 2017 in our hospital as the case group, and 86 cases of febrile children were selected as the control group in the same period. The single factor of febrile convulsion was analyzed, the clinical data in both groups were analyzed, the possible risk factors of febrile convulsion were observed, and the relationship between immunoglobulin, trace elements and its occurrence was analyzed. Results: There was no significant difference in sex. age and mode of delivery between the control group and the case group (P>0.05). There were significant differences in body temperature, family history of convulsion, perinatal injury, poor living environment, creatine kinase MB isoenzyme (CK-MB) , immunoglobulin and trace elements between the two groups (P<0.05). Multivariate unconditional logistic regression analysis showed that body temperature, family history of convulsion, perinatal injury, poor living environment and CK-MB were independent risk factors for febrile convulsion. Immunoglobulin and trace elements were protective factors for febrile convulsion (P<0.05). Conclusion: The occurrence of febrile convulsion is related to a variety of high-risk factors. Low levels of immunoglobulin and trace elements can participate in the occurrence of febrile convulsion. Clinical intervention may reduce the risk of febrile convulsion.

目的 通过观察热性惊厥患儿血浆中神经肽B(NPB)、神经肽Y(NPY)、甘丙肽(GAL)水平,探讨NPB、NPY、GAL在热性惊厥发病中的作用.方法 选取热性惊厥患儿(6个月～6岁)50例为实验组[其中单纯性热性惊厥(SFS)组36例,复杂性热性惊厥(CFS)组14例],同时选自本院同期住院期间发热但未发生惊厥的40例患儿为观察组,门诊正常体检儿童40例为对照组,采用酶联免疫吸附法和放射免疫分析法检测血浆中NPB、NPY、GAL水平.结果 (1)热性惊厥后第1天实验组NPB、NPY、GAL水平均明显上升,与观察组、对照组比较,差异有统计学意义(P<0.05);观察组NPB、NPY和GAL水平略高于对照组,但差异无统计学意义(P>0.05).(2)热性惊厥后第7天实验组NPY、GAL水平仍明显升高,与观察组比较,差异有统计学意义(P<0.01),而实验组NPB水平较前下降,与同期观察组比较,差异无统计学意义(P>0.05),与热性惊厥后第1天比较差异有统计学意义(P<0.01).(3)惊厥后第1天CFS组患儿NPB、NPY和GAL水平明显高于SFS组患儿,差异均有统计学意义(P<0.05).(4)惊厥后第7天CFS组患儿NPY和GAL水平明显高于SFS患儿,差异有统计学意义(P<0.05).结论 热性惊厥发作后第1天,患儿血浆中NPB、NPY、GAL水平增高;热性惊厥发作第7天时,NPY、GAL水平仍增高,而NPB水平下降,NPB、NPY、GAL水平增高程度与惊厥发作程度及惊厥发作次数相关,表明NPB、NPY、GAL可能与热性惊厥的发病及病情进展有关.

目的:分析过敏性紫癜(HSP)患儿血清中干扰素-γ(IFN-γ)、白细胞介素10(IL-10)和转化生长因子-β(TGF-β)及穿孔素(PFP)、颗粒溶素(GNLY)的表达水平,并探讨其表达意义.方法:选择本院收治的86例HSP患儿作为研究对象(HSP组),根据是否合并肾损伤分为肾损伤组41例和无肾损伤组45例,同时期40例健康儿童为对照组.采用酶联免疫吸附实验(ELISA)检测受试儿童血清IFN-γ 、IL-10和TGF-β 表达水平,RT-PCR检测血清PFP、GNLY表达水平,比较不同组之间差异,并分析HSP组血清IFN-γ 、IL-10、TGF-β 、PFP、GNLY之间的关系.结果:HSP组血清IFN-γ 、PFP、GNLY水平低于对照组(P<0.05),血清IL-10、TGF-β 水平高于对照组(P<0.05);肾损害组血清IFN-γ 、PFP、GNLY水平低于无肾损害组(P<0.05),血清IL-10、TGF-β 水平高于无肾损害组(P<0.05);HSP组血清IFN-γ 与TGF-β 呈负相关关系(r=-0.417,P=0.037),与PFP、GNLY分别呈正相关关系(r=0.508、0.477,P=0.025、0.030);IL-10与TGF-β 呈正相关关系(r=0.514,P=0.017).结论:血清IFN-γ 、IL-10、TGF-β 、PFP、GNLY水平变化与HSP发生及进展密切相关,早期检测有助于HSP病情评估,对临床预防过敏性紫癜肾炎的发生具有指导意义.

目的 探讨盐酸哌甲酯联合行为矫正治疗儿童注意缺陷多动障碍的临床疗效.方法 选取陕西省人民医院儿科自2015年3月至2017年2月收治的150例注意缺陷多动障碍患者,按随机数字表分法分为A、B两组,每组各75例患儿.A组给予常规疗法和行为矫正联合治疗,B组采取盐酸哌甲酯辅助行为矫正治疗.比较两组患儿治疗前及治疗后的Conners父母用量表、综合反应控制力商数(FRCQ)和综合注意力商数(FAQ)及临床疗效.结果 治疗后,B组患儿品行问题、学习问题、身心障碍、冲动-多动、多动指数因子分显著低于A组,差异均有统计学意义(P<0.05);但两组焦虑因子分比较,差异无统计学意义(P>0.05).治疗后,B组的FRCQ、FAQ总分明显大于A组,差异均有统计学意义(P<0.05).B组临床治疗有效率为93.3％(70/75),明显大于A组的81.3％(61/75),差异有统计学意义(P<0.05).结论 盐酸哌甲酯辅助行为矫正能有效提高注意缺陷多动障碍患儿的注意力,减少患儿的行为冲动,从而提高其自我控制能力,促进临床疗效.

Objective To investigate the diagnostic value of Peptides and Interleukin-17A,Tumor necrosis factorαin children kawasaki coronary artery disease.Methods 60 patients,made a definite diagnosis as kawasaki coronary artery disease(32 cases of male,28 cases of female,average age 2.5 years),40 healthy subject were enrolled in the study(23 cases of male,fe-male 17 cases,with an average age of 3 years of age).The plasma levels of Peptides,Interleukinin 17A(IL-17A)and Tumor necrosis factorα(TNF-α)in each group was detected by ELISA.Results ①The plasma levels of Peptides,Interleukinin 17A (IL-17A)and Tumor necrosis factorα(TNF-α)was significantly higher than healthy controls,respectively(21.09±2.72) vs(18.45±2.96)pmol/L,t=6.13,P<0.01,(21.20±2.35)vs(18.80±2.20)pg/ml,t=8.586,P<0.01;(50.84±5.81) vs(45.24±6.15)pg/ml,t=7.278,P<0.01.②Results of ROC curves showed,the sensitivity of Peptides in kawasaki coro-nary artery disease was 88.2%,the specificity was 75.0% and the sensitivity of IL-17A was 85.3%,the specificity was 79.2%,the sensitivity of TNF-αwas 88.2%,the specificity was 73.6%.Conclusion The plasma levels of Peptides,IL-17A and TNF-αin acute phase of kawasaki coronary artery disease were all increased.Combined detections of peptide,IL-17A and TNF-αmay predict the incidence of coronary artery disease in children with kawasaki disease.

目的:研究止嗽散合二陈汤结合西医常规治疗支气管炎患儿的临床疗效.方法:选取支气管炎患儿116例,采用随机数字法将其分为对照组和观察组,每组58例.对照组患儿给予西医对症治疗,包括抗感染、退热加镇咳化痰,在此基础上,观察组患儿给予止嗽散合二陈汤治疗.比较两组患儿的治疗疗效和不良反应,同时比较治疗前后的临床评分.结果:观察组的治疗总有效率(94.83%)明显高于对照组(81.03%)(χ2=5.19,P=0.02);观察组治疗后的临床评分明显低于对照组(P<0.05),观察组的体温恢复时间、咳嗽痰响消失时间、干湿性啰音消失时间、住院时间均明显低于对照组(P<0.05),两组的不良反应发生率比较无差异统计学意义(P>0.05).结论:止嗽散合二陈汤结合西医治疗支气管炎患儿的具有较高的疗效,且治疗安全性高.

Objective To study the clinical effect of Pudilan Xiaoyan Oral Liquid combined with Zedoary Turmeric Oil and Glucose Injection in treatment of children herpangina. Methods Children (92 cases) with herpangina in Childrens' Hospital of Shaanxi Provincial People's Hospital from May 2016 to May 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Children in the control group were iv administered with Zedoary Turmeric Oil and Glucose Injection, the dosage was 10 mg/(kg·d),once daily.Children in the treatment group were po administered with Pudilan Xiaoyan Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Children in two groups were treated for 1 week. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms and signs, and serum levels of IL-6, IL-10 and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 86.96%, which was significantly lower than 97.83% in the treatment group, and the difference was statistically significant between two groups (P < 0.05). After treatment, the disappearance time of clinical symptoms, fever and herpes in the treatment group was shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the serum IL-6, IL-10 and TNF-α level in two groups was significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the serum inflammatory factor level in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Pudilan Xiaoyan Oral Liquid combined with Zedoary Turmeric Oil and Glucose Injection can significantly shorten the disappearance time of clinical symptoms and signs, and reduce the inflammatory level in treatment of children herpangina, which has a certain clinical application value.